Capgemini and the world's leading life sciences organisations collaborate to enable change through insight and technology.
Thought Leadership
A bitter pill or miracle cure? The drive towards the restructuring of UK pharmaceutical distribution
Opportunity for pharma to reduce counterfeiting and improve comparative advantage through exclusive distribution.
Read moreThought Leadership
Global research report - Vision & Reality 6th Edition
From Market to Discovery and Back: The Value of Early Commercialisation.
With rising income levels across most parts of the world, patient aspirations and demands are increasing. However, pharmaceutical firms are facing a dangerous combination of high costs and falling revenues as drugs fall out of patent protection. Drug safety remains key and competition within the industry is intensifying. Periods of market exclusivity enjoyed by drugs that are first to market are increasingly diminished with the swift onslaught of fast followers. Complexity is on the rise, for example the pharmaceutical industry faces the increasing fragmentation of their customer base; pharmaceutical firms now have to sell not just to physicians but to a multi-tiered and networked audience.
These industry challenges leave pharmaceutical firms increasingly in the spotlight, and often under fire, as they tread the fine line between delivering life changing value to consumers amidst the backlash of being one of the most profitable of all industries. Our team of life sciences experts is able to share insights into the most critical business issues facing this industry right now, because we are the No. 1 global life sciences consulting practice. In each of the sectors of the industry, pharmaceuticals, biotechnology, medical devices, and agribusiness, we provide clients with industry-specific solutions covering marketing and sales, supply chain management, research and development, global regulatory compliance, outsourcing and product lifecycle management.
Our UK team is part of a global network of more than 500 professionals and 2,500 affiliated consultants in 19 countries with specific expertise in the field of Life Sciences. Our UK consultants often have international experience, and are used to working on multinational as well as UK only projects. For more information, please visit the Life Sciences global website.
“The firm ranked 1st in the life sciences category, 1st in the provider category, and 1st in the insurer/payer category in Kennedy’s Information ranking of the largest healthcare consulting practices.”
Source: Kennedy: The Global Outlook of the Healthcare Consulting Marketplace, Various Analysts
